Evogene Ltd Company Profile (NYSE:EVGN)

About Evogene Ltd (NYSE:EVGN)

Evogene Ltd logoEvogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Industry, Sector and Symbol:
  • Sector: Non-Cyclical Consumer Goods & Services
  • Industry: Agricultural Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSE:EVGN
  • CUSIP: N/A
  • Web: www.evogene.com/
Capitalization:
  • Market Cap: $120.49 million
  • Outstanding Shares: 25,745,000
Average Prices:
  • 50 Day Moving Avg: $4.50
  • 200 Day Moving Avg: $4.94
  • 52 Week Range: $4.22 - $6.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.37
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.61 million
  • Price / Sales: 26.14
  • Book Value: $3.08 per share
  • Price / Book: 1.52
Profitability:
  • EBITDA: ($19,560,000.00)
  • Net Margins: -235.47%
  • Return on Equity: -18.60%
  • Return on Assets: -17.16%
Debt:
  • Current Ratio: 17.05%
  • Quick Ratio: 17.04%
Misc:
  • Average Volume: 7,953 shs.
  • Beta: 0.61
  • Short Ratio: 0.3
 

Frequently Asked Questions for Evogene Ltd (NYSE:EVGN)

What is Evogene Ltd's stock symbol?

Evogene Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVGN."

How were Evogene Ltd's earnings last quarter?

Evogene Ltd (NYSE:EVGN) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.05. The firm earned $1.18 million during the quarter. Evogene Ltd had a negative return on equity of 18.60% and a negative net margin of 235.47%. View Evogene Ltd's Earnings History.

When will Evogene Ltd make its next earnings announcement?

Evogene Ltd is scheduled to release their next quarterly earnings announcement on Monday, November, 20th 2017. View Earnings Estimates for Evogene Ltd.

Who are some of Evogene Ltd's key competitors?

Who are Evogene Ltd's key executives?

Evogene Ltd's management team includes the folowing people:

  • Martin S. Gerstel, Chairman of the Board
  • Ofer Haviv, President, Chief Executive Officer
  • Alex Taskar, Chief Financial Officer
  • Yuval Ben-Galim, Chief Operating Officer
  • Hagai Karchi, Executive Vice President, Chief Technology Officer
  • Amos Shachar, Vice President of Project Management
  • Lea Slonim Bloom, Director of Administration & Human Resources
  • Sarit Firon, Director
  • Adina Makover, Director
  • Leon Yehuda Recanati, Director

How do I buy Evogene Ltd stock?

Shares of Evogene Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evogene Ltd's stock price today?

One share of Evogene Ltd stock can currently be purchased for approximately $4.68.


MarketBeat Community Rating for Evogene Ltd (NYSE EVGN)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about Evogene Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Evogene Ltd (NYSE:EVGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Evogene Ltd (NYSE:EVGN)
Price Target History for Evogene Ltd (NYSE:EVGN)
Analysts' Ratings History for Evogene Ltd (NYSE:EVGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/17/2016Credit Suisse GroupLower Price TargetOutperform$19.00 -> $10.00N/AView Rating Details
11/19/2015Piper Jaffray CompaniesLower Price TargetNeutral$12.00 -> $8.00N/AView Rating Details
(Data available from 10/16/2015 forward)

Earnings

Earnings History for Evogene Ltd (NYSE:EVGN)
Earnings by Quarter for Evogene Ltd (NYSE:EVGN)
Earnings History by Quarter for Evogene Ltd (NYSE EVGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/20/2017        
8/10/20176/30/2017($0.13)($0.18)$1.18 millionViewN/AView Earnings Details
5/17/20173/31/2017($0.18)($0.19)$0.72 millionViewN/AView Earnings Details
2/27/2017Q4($0.18)($0.26)$1.18 millionViewListenView Earnings Details
11/21/2016Q3($0.07)($0.20)$1.54 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.18)$5.36 million$3.82 millionViewListenView Earnings Details
5/19/2016Q1($0.11)($0.13)$2.70 million$2.00 millionViewListenView Earnings Details
3/1/2016Q415($0.17)($0.22)$3.90 million$2.46 millionViewN/AView Earnings Details
11/18/2015Q315($0.15)($0.13)$3.50 million$3.31 millionViewListenView Earnings Details
8/5/2015Q215($0.19)($0.20)$4.40 million$2.66 millionViewN/AView Earnings Details
5/19/2015Q115($0.20)($0.13)$3.65 million$2.70 millionViewListenView Earnings Details
2/26/2015Q4($0.12)($0.19)$3.64 millionViewN/AView Earnings Details
11/10/2014Q314($0.10)($0.17)$4.20 million$3.16 millionViewN/AView Earnings Details
8/20/2014Q214($0.11)($0.13)$4.77 million$3.85 millionViewN/AView Earnings Details
5/7/2014Q1 14($0.13)($0.09)$5.40 million$3.86 millionViewN/AView Earnings Details
3/19/2014Q413($0.08)($0.20)$4.95 million$4.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Evogene Ltd (NYSE:EVGN)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS

Dividends

Dividend History for Evogene Ltd (NYSE:EVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Evogene Ltd (NYSE:EVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Evogene Ltd (NYSE:EVGN)
Latest Headlines for Evogene Ltd (NYSE:EVGN)
Source:
DateHeadline
americanbankingnews.com logo-$0.19 Earnings Per Share Expected for Evogene Ltd (EVGN) This Quarter
www.americanbankingnews.com - October 16 at 2:08 AM
finance.yahoo.com logoETFs with exposure to Evogene Ltd. : October 5, 2017
finance.yahoo.com - October 5 at 5:38 PM
finance.yahoo.com logoEvogene Ltd. :EVGN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 5:16 PM
feeds.benzinga.com logoEvogene & Rahan Meristem announce positive results in 2nd year field trials addressing Black Sigatoka disease in banana and the utilization of the results for genome editing
feeds.benzinga.com - September 26 at 8:06 AM
feeds.benzinga.com logoEvogene to Present at the 26th Asian-Pacific Weed Science Society Conference
feeds.benzinga.com - August 23 at 7:40 AM
americanbankingnews.com logoEvogene Ltd (EVGN) Releases Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - August 10 at 7:46 PM
americanbankingnews.com logoEvogene Ltd (NYSE:EVGN) to Release Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:16 AM
americanbankingnews.com logo Analysts Expect Evogene Ltd (NYSE:EVGN) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - August 2 at 8:20 PM
streetinsider.com logoEvogene (EVGN) Enters Multiyear Research Collaboration for Development of Corn Bio-Stimulant Products with DuPont (DD)
www.streetinsider.com - July 27 at 5:05 AM
finance.yahoo.com logoCompany News for July 12, 2017
finance.yahoo.com - July 12 at 7:07 PM
baystreet.ca logoEvogene Pops on New Phase of Monsanto Partnership
www.baystreet.ca - July 11 at 7:37 PM
finance.yahoo.com logoEvogene Achieves Important Milestone in Monsanto Crop Disease Collaboration
finance.yahoo.com - July 11 at 7:37 PM
americanbankingnews.com logoEvogene Ltd (EVGN) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 11 at 2:30 PM
finance.yahoo.com logoETFs with exposure to Evogene Ltd. : July 4, 2017
finance.yahoo.com - July 5 at 5:20 AM
feeds.benzinga.com logoEvogene Reports First Quarter 2017 Financial Results
feeds.benzinga.com - May 17 at 8:12 AM
feeds.benzinga.com logoEvogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit
feeds.benzinga.com - March 7 at 7:28 AM
seekingalpha.com logoEvogene's (EVGN) CEO Ofer Haviv on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 7:24 PM
globenewswire.com logoEvogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers
globenewswire.com - February 14 at 6:04 PM
streetinsider.com logoEvogene (EVGN) to Move from NYSE to NASDAQ
www.streetinsider.com - December 20 at 6:40 PM
us.rd.yahoo.com logo4:33 pm Evogene to transfer its stock exchange listing to the NASDAQ Global Market from the New York Stock Exchange
us.rd.yahoo.com - December 20 at 10:10 AM
streetinsider.com logoEvogene (EVGN) Announces Positive Efficacy, Stability Results from Ag-Biologicals Program Field Trial
www.streetinsider.com - November 17 at 5:41 AM
streetinsider.com logoEvogene (EVGN), IMAmt Enter Insect-Resistant Cotton Seed R&D Collaboration
www.streetinsider.com - October 20 at 10:25 AM
streetinsider.com logoCredit Suisse Cuts Price Target on Evogene (EVGN) to $10 Following 2Q
www.streetinsider.com - August 17 at 10:11 PM

Social

Chart

Evogene Ltd (EVGN) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.